Clinical Trial Update: Efficacy and Safety of AFQ056 in Reducing L-dopa Induced Dyskinesias in Parkinson's Disease Patients [Phase 2]

View source ↗

Summary

Phase 2 trial assessing the efficacy and safety of AFQ056 to reduce L-dopa-induced dyskinesias in Parkinson's disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• L-dopa-induced Dyskinesia
• Parkinson Disease

Drugs mentioned

• AFQ056 (mavoglurant)

Snippet

Sponsor: Novartis | Conditions: Parkinson's Disease, L-dopa Induced Dyskinesia | Phase 2 | Status: COMPLETED